Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinobufacini Combined With TACE for Primary Liver Cancer
NCT03843229Phase 4Unknown
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cinobufacini in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Tumor Size at 8 weeks. Status: unknown.
02
Drugs
cinobufacini
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03843229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843229.